阿司匹林肠溶片联合阿托伐他汀预防脑梗死再发疗效观察

Effect Observation of Bayaspirin Combined with Atorvastatin on Prevention of Recurrent Cerebral Infarction

目的:探讨阿司匹林肠溶片联合阿托伐他汀预防脑梗死再发的临床疗效。方法:120例急性脑梗死患者随机分为对照组与观察组各60例,两组均给予急性脑梗死常规治疗,对照组同时予阿司匹林肠溶片150 mg,po,qn;观察组同时予阿司匹林肠溶片150 mg,po,qn,阿托伐他汀片10～20 mg,po,qn。比较两组患者治疗1年后病死率、脑缺血事件发生率及血脂、高敏C反应蛋白(hs-CRP)的改变。结果:治疗后1年,两组患者病死率分别为3.3%和5.0%(P>0.05);但观察组脑缺血事件发生率显著低于对照组(15.0%vs 36.7%,P<0.05);观察组三酰甘油(TG)、总胆固醇(TC)、低密度脂蛋白(LDL)及hs-CRP水平显著低于对照组(P<0.01)。结论:阿司匹林联合阿托伐他汀治疗脑梗死,可显著降低血脂及hs-CRP水平,减少脑缺血事件发生率,在脑血管病二级预防中应给予多方面的综合治疗。

Objective ： To explore the effect of bayaspirin combined with atorvastatin on prevention of recurrent cerebral infarction. Method： 120 cases with acute cerebral infarction were randomly divided into the control group and the observation group with 60 pa- tients each. The control group were received bayaspirin 150 mg po, qn, and the observation group was given bayaspirin combined with atorvastatin 10-20 mg po, qn. The mortality, incidence of cerebral ischemia, the changes in blood lipid and C-reaction protein pre and post the treatment were compared between the two groups. Result： The mortality after one year post the treatment was 3.3% and 5.0% in the observation group and the control group, respectively （ P 〉 0.05 ）. Incidence of cerebral isehemia in the observation group was 15.0%, which was significantly lower than that （36.7%） in the control group （P 〈 0.05）. TG, TC, LDL and hs-CRP after the treatment in the observation group was also significantly lower than those in the control group （P 〈 0.01 ）. Conclusion： Bayaspirin combined with atorvastatin in the treatment of cerebral infarction can significantly decrease the blood lipid and hs-CRP level, and re- duce the incidence of cerebral ischemia. Combined therapy should be performed in the secondary prevention of cerebrovascular disea- ses,